2025. Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), s532. DOI:https://doi.org/10.25251/skin.10.supp.532.